Nivolumab Injection 100 mg Opdyta

Trade Name: Opdyta

Manufacturer: BMS India Pvt Ltd

Presentation: Injection

Strength: 100mg


What is the purpose of Nivolumab Injection?

Nivolumab Injection is an immunotherapy medication, which is a sort of cancer treatment. It is a cancer treatment that is used to treat a variety of cancers. It could be part of a clinical trial for a different type of cancer.

What is Opdyta and how does it work?

Opdyta is a monoclonal antibody (nye VOL ue mab). Melanoma, lung cancer, cell lung cancer, kidney, head, and neck cancer, Hodgkin lymphoma, urothelial cancer, colon cancer, and liver cancer are all treated with this drug.

How effective is nivolumab?

Findings: Overall survival with Nivolumab Injection was 14 percent (95 percent CI 11-17) for all patients (n=664) in all four studies, 19 percent (15-24) for those with at least 1% PD-L1 expression, and 11 percent (7-16) for those with less than 1% PD-L1 expression.

How is nivolumab administered?

Every two weeks, Nivolumab is given intravenously (IV) into a vein for 60 minutes. The amount of nivolumab you receive is determined by a number of criteria, including your overall health or other health issues, as well as the type of disease or illness being treated.

How can I tell whether nivolumab is effective?

  • Your doctor will conduct periodic tests like CT (computed tomography
  • and PET (positron emission tomography) scans,
  • as well as an MRI, to see if you’re responding to Opdivo medication (magnetic resonance imaging).

Do you take nivolumab for a long time?

It takes roughly 60 minutes to complete each dose. Unless their melanoma develops or they have significant side effects, patients are normally given nivolumab every two weeks. Nivolumab is an outpatient treatment that does not require a hospital stay.

Is nivolumab associated with a fever?

Fever was reported in 17 (18%) of the Nivolumab individuals. Fever was caused by ICI in 12 (70%) cases, infection in 4 (24%) cases, and other in 1 case (6 percent ). Patients who had a fever after receiving nivolumab had a significantly shorter PFS than those who did not (median, 40 vs 123.5 days; 95 percent confidence intervals [CI], 14-162 vs 70-178 days; p=.

If you are looking for another product or brand click here.